Antimicrobial Agents and Chemotherapy · 2015 · 118 citations · 7 references
Life SciencesMicrobiologyPharmacologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAntibacterial ResistanceAntibacterial TherapyAntibiotic ResistanceAntimicrobial Susceptibility TestingBeta-lactam ResistanceCarbapenem ResistanceBeta-lactamase InhibitorsEscherichia ColiExtended-spectrum Beta-lactamase InhibitorsExtended-spectrum Beta-lactamase Producing OrganismsExtended-spectrum Beta-lactamase ProductionExtended-spectrum Beta-lactamase-producing OrganismsExtended-spectrum Beta-lactamasesKlebsiella Pneumoniae Resistance
Ceftazidime-avibactam (MIC50/90, 0.12/0.25 μg/ml) inhibited 99.9% (20,698/20,709) of Enterobacteriaceae isolates at ≤8 μg/ml. This compound was active against resistant subsets, including ceftazidime-nonsusceptible Enterobacter cloacae (MIC50/90, 0.25/0.5 μg/ml) and extended-spectrum β-lactamase (ESBL) phenotype isolates. An ESBL phenotype was noted among 12.4% (1,696/13,692 isolates from targeted species) of the isolates, including 776 Escherichia coli (12.0% for this species; MIC50/90, 0.12/0.25 μg/ml), 721 Klebsiella pneumoniae (16.3%; MIC50/90, 0.12/0.25 μg/ml), 119 Klebsiella oxytoca (10.3%; MIC50/90, 0.06/0.25 μg/ml), and 80 Proteus mirabilis (4.9%; MIC50/90, 0.06/0.12 μg/ml) isolates. The most common enzymes detected among ESBL phenotype isolates from 2013 (n = 743) screened using a microarray-based assay were CTX-M-15-like (n = 307), KPC (n = 120), SHV ESBLs (n = 118), and CTX-M-14-like (n = 110). KPC producers were highly resistant to comparators, and ceftazidime-avibactam (MIC50/90, 0.5/2 μg/ml) and tigecycline (MIC50/90, 0.5/1 μg/ml; 98.3% susceptible) were the most active agents against these strains. Meropenem (MIC50/90, ≤0.06/≤0.06 μg/ml) and ceftazidime-avibactam (MIC50/90, 0.12/0.25 μg/ml) were active against CTX-M-producing isolates. Other enzymes were also observed, and ceftazidime-avibactam displayed good activity against the isolates producing less common enzymes. Among 11 isolates displaying ceftazidime-avibactam MIC values of >8 μg/ml, three were K. pneumoniae strains producing metallo-β-lactamases (all ceftazidime-avibactam MICs, >32 μg/ml), with two NDM-1 producers and one K. pneumoniae strain carrying the bla(KPC-2) and bla(VIM-4) genes. Therapeutic options for isolates producing β-lactamases may be limited, and ceftazidime-avibactam, which displayed good activity against strains, including those producing KPC enzymes, merits further study in infections where such organisms occur.
7
Alicia Hidrón, Jonathan R. Edwards, Jean B. Patel et al. · Infection Control and Hospital Epidemiology · 2008 · 3.8K citations
Dawn Sievert, Philip Ricks, Jonathan R. Edwards et al. · Infection Control and Hospital Epidemiology · 2012 · 1.6K citations
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17
S. B. Debast, Martijn P. Bauer, Ed J. Kuijper · Clinical Microbiology and Infection · 2013 · 1.2K citations · Full text
Mariana Castanheira, Sarah E. Farrell, Kevin M. Krause et al. · Antimicrobial Agents and Chemotherapy · 2013 · 177 citations · Full text
Mariana Castanheira, Sarah E. Farrell, Lalitagauri M. Deshpande et al. · Antimicrobial Agents and Chemotherapy · 2013 · 112 citations · Full text